WO2025238557 - CHOLESTEROL CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
National phase entry is expected:
Publication Number
WO/2025/238557
Publication Date
20.11.2025
International Application No.
PCT/IB2025/055020
International Filing Date
13.05.2025
Title **
[English]
CHOLESTEROL CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
[French]
CONTRÔLE DU CHOLESTÉROL AVEC DES FORMULATIONS DE COMPLEXES D'INCLUSION DE CYCLODEXTRINE ENZYMATIQUE
Applicants **
CZAP RESEARCH AND DEVELOPMENT, LLC
Inventors
CZAP, Al
Priority Data
63/646,378
13.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2475 | |
| EPO | Filing, Examination, Granting | 18302 | |
| Japan | Filing, Examination, Granting | 2575 | |
| South Korea | Filing, Examination, Granting | 2975 | |
| USA | Filing, Examination, Granting | 5910 |
Total:
32,237
Contact Us
Abstract[English]
The invention provides oral cyclodextrin inclusion complex formulations in which inclusion complexes of camphene from the camphene CD inclusion complex; borneol from the borneol CD inclusion complex; geraniol from the geraniol CD inclusion complex; and, anethole from the anethole CD inclusion complex are provided together with an enzyme having a cyclodextrin-degrading activity capable of digesting cyclodextrins, so that upon delivery of the formulation to a target tissue the CD-degrading enzyme is activated and releases the camphene from the camphene CD inclusion complex; borneol from the borneol CD inclusion complex; geraniol from the geraniol CD inclusion complex; and, anethole from the anethole CD inclusion complex from the cyclodextrins. These cyclodextrin inclusion complex formulations may be used for lowering cholesterol, triglycerides and/or LDL levels.[French]
L'invention concerne des formulations orales de complexes d'inclusion de cyclodextrine dans lesquelles des complexes d'inclusion de camphène provenant du complexe d'inclusion CD de camphène; de bornéol provenant du complexe d'inclusion CD de bornéol ; de géraniol provenant du complexe d'inclusion CD de géraniol ; et, d'anéthole provenant du complexe d'inclusion CD d'anéthole sont pourvus conjointement d'une enzyme ayant une activité de dégradation de cyclodextrine capable de digérer les cyclodextrines, de telle sorte que, lors de l'administration de la formulation à un tissu cible, l'enzyme de dégradation de CD est activée et libère le camphène du complexe d'inclusion CD de camphène ; le bornéol du complexe d'inclusion CD de bornéol ; le géraniol du complexe d'inclusion CD de géraniol ; et, l'anéthole du complexe d'inclusion CD de d'anéthole à partir des cyclodextrines. Ces formulations de complexes d'inclusion de cyclodextrine peuvent être utilisées pour abaisser le cholestérol, les triglycérides et/ou les niveaux de LDL.